Galapagos initiates Phase 1 study

Galapagos initiates Phase 1 study with cystic fibrosis drug GLPG2737

http://sports.yahoo.com/news/galapagos-initiates-phase-1-study-210201858.html

Galapagos NV (Euronext & NASDAQ: GLPG) reports the initiation of a Phase 1 study in healthy volunteers with GLPG2737, a novel C2 corrector drug for cystic fibrosis. Initiation of the Phase 1 study triggers a $10 million milestone payment from AbbVie.

The aim of the Phase 1 study is to evaluate the safety, tolerability and Continue reading Galapagos initiates Phase 1 study

Vertex to test new class of CF drugs

Vertex to test new class of cystic fibrosis drugs in patients

https://www.bostonglobe.com/business/2016/10/25/vertex-test-new-class-cystic-fibrosis-drugs-patients/IcwjZhIPc2YXyguss2OGSM/story.html

Vertex Pharmaceuticals Inc. said Tuesday it will begin clinical trials for a new class of “triple combination” drug candidates that could nearly double the Continue reading Vertex to test new class of CF drugs

Vertex ends trial of cystic fibrosis drug combination

https://www.bostonglobe.com/business/2016/08/15/vertex-ends-trial-cystic-fibrosis-drug-combination/6AkHgBOmtKPF9XRgq18IQM/story.html

Vertex Pharmaceuticals Inc. said Monday it is ending a clinical study testing a two-drug combination therapy on a small group of cystic fibrosis patients after an independent board concluded the experimental treatment wasn’t showing Continue reading Vertex ends trial of cystic fibrosis drug combination

OWN IT: Living with CF GoPro Part II

This GoPro video definitely shows a behind the scenes look at my life with cystic fibrosis. I tried to capture the maintenance that my body requires for it to fully function. Beyond that I really wanted to give a first person point of view of my Continue reading OWN IT: Living with CF GoPro Part II

Therapeutically robust correction, in vitro, of the most common cystic fibrosis mutation

http://www.medicalnewstoday.com/releases/310582.php

Cystic fibrosis lung cells were restored to 50 percent of healthy function in work that provides the first evidence that novel therapeutic strategies for human patients can be identified based on yeast studies.

In experiments with isolated cystic fibrosis lung cells, University of Alabama at Continue reading Therapeutically robust correction, in vitro, of the most common cystic fibrosis mutation

Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis

https://globenewswire.com/news-release/2016/05/16/840427/0/en/Nivalis-Therapeutics-Announces-First-Patient-Dosed-in-Second-Phase-2-Study-of-N91115-for-Treatment-of-Cystic-Fibrosis.html

Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced the first patient was dosed in a second Phase 2 clinical study of Continue reading Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis

Galapagos starts Phase 1 study with potentiator GLPG2451 for CF

http://finance.yahoo.com/news/galapagos-starts-phase-1-study-200909850.html

Galapagos NV (Euronext & NASDAQ: GLPG) announces the start of a Phase 1 study with potentiator GLPG2451 for cystic fibrosis (CF). Following GLPG1837, GLPG2451 is the second potentiator compound in Galapagos’ extended CF-portfolio to enter clinical trials.

Galapagos is conducting a randomized, double-blind, placebo-controlled Continue reading Galapagos starts Phase 1 study with potentiator GLPG2451 for CF

Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines

http://www.nasdaq.com/press-release/editas-medicine-announces-agreement-with-cystic-fibrosis-foundation-therapeutics-to-advance-new-20160516-00255

Editas to Receive up to $5 Million Award to Fund Genome Editing Research

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced a three-year agreement with Cystic Fibrosis Foundation Continue reading Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines

Corbus bets on cystic-fibrosis market with Resunab

http://www.mmm-online.com/pipeline/corbus-bets-on-cystic-fibrosis-market-with-resunab/article/485565/

While CFTR modulators have stolen the cystic fibrosis treatment spotlight, Corbus Pharmaceuticals has quietly tackled CF’s inflammatory and fibrotic components. Resunab, Corbus’s investigative agent, has the potential to Continue reading Corbus bets on cystic-fibrosis market with Resunab

The Paradox of Precision Medicine

http://www.scientificamerican.com/article/the-paradox-of-precision-medicine/

Precision medicine sounds like an inarguably good thing. It begins with the observation that individuals vary in their genetic makeup and that their diseases and responses to medications differ as a result. It then aims to find the right drug, for the right patient, at the Continue reading The Paradox of Precision Medicine